Raltegravir en pacientes con infección por el virus de la inmunodeficiencia humana y alto riesgo vascular / Raltegravir in HIV-infected patients with high vascular risk
Med. clín (Ed. impr.)
; 138(3): 107-109, feb. 2012.
Artigo
em Espanhol
| IBECS
| ID: ibc-98047
Biblioteca responsável:
ES1.1
Localização: BNCS
RESUMEN
Introducción:
Nos proponemos recoger la experiencia de uso de raltegravir en el contexto del tratamiento antirretroviral de gran actividad (TARGA) en pacientes de alto riesgo vascular.Método:
Estudio retrospectivo de casos y controles. Los casos fueron aquellos pacientes que al comenzar con raltegravir presentaban un riesgo de enfermedad cardiovascular ≥ 20% según el algoritmo de la Sociedad Europea de Sida. Debían haber permanecido con dicho tratamiento durante al menos seis meses. Se parearon controles 11 con riesgo vascular también ≥ 20%.Resultados:
Se seleccionaron diez casos y diez controles. Tras seis meses de uso de raltegravir, se observó un descenso de los valores de colesterol unido a lipoproteínas de alta densidad (colesterol HDL) (-2,5mg/dL en los controles frente a 2,5mg/dL en los casos, p=0,015), triglicéridos (10mg/dL frente a -101mg/dL, p=0,009), y en la ratio colesterol total/colesterol HDL (0,17 frente a -0,73, p=0,002). El riesgo de enfermedad cardiovascular a diez años disminuyó un 4,85% en los casos frente a un 0,05% en los controles (p=0,07).Conclusiones:
Raltegravir muestra un buen perfil para ser usado en pacientes de alto riesgo vascular, con descenso de la ratio colesterol total/colesterol HDL y del riesgo vascular (AU)ABSTRACT
Objectives:
To record the experience with use of raltegravir (RTG) for devising highly active antiretroviral therapy (HAART) regimens based on RTG in high vascular risk patients.Methods:
A retrospective study was conducted on high vascular risk patients taking RTG. Case was a patient who, at the time raltegravir was started, had ≥ 20% 10-year risk of cardiovascular disease, estimated by the algorithm of the European AIDS Clinical Society. Patients should have been on stable HAART including RTG for at least six months. A matched control with ≥ 20% risk of cardiovascular disease, was selected for each case.Results:
Ten controls and ten cases were selected. After six months using RTG, a significant decreased was seen in levels of HDL cholesterol (median -2,5mg/dL in controls versus 2,5mg/dL in cases, p=0.015), triglycerides (10mg/dL versus -101mg/dL, p=0.009), and TC/HDL-C ratio (0.17 versus -0.73, p=0.002). Ten-year risk of cardiovascular disease was -4.85% in cases versus -0.05% in controls (p=0.07).Conclusions:
RTG shows a good profile to be used in people with high vascular risk, with a decrease in TC/HDL-C ratio and vascular risk (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
Base de dados:
IBECS
Assunto principal:
Doenças Cardiovasculares
/
Infecções por HIV
/
Inibidores de Hidroximetilglutaril-CoA Redutases
Tipo de estudo:
Estudo de etiologia
/
Estudo observacional
Limite:
Humanos
Idioma:
Espanhol
Revista:
Med. clín (Ed. impr.)
Ano de publicação:
2012
Tipo de documento:
Artigo
Instituição/País de afiliação:
Distrito Sanitario d ela Costa del Sol/España
/
Hospital Costa del Sol/España